Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1885-1889

  Weiss, Raymond B ^a   Freiman, Joel ^a   Kweder, Sandra L ^a   Diehl, Louis F ^a   Byrd, John C ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ERYTHROCYTE ANTIGEN; FLUDARABINE PHOSPHATE;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HEMATOCRIT; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031860122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1885     Document Type: Article

References (26)

1. Han T, Ezdinli EZ, Shimaoka K, et al.: Chlorambucil versus combined chlorambucil corticosteroid therapy in chronic lymphocytic leukemia. Cancer 31:502-508, 1973
2. Sawitsky A, Rai KR, Glidewell O, et al.: Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treat-ment of patients with chronic lymphocytic leukemia. Blood 50:1049-1059,1977
3. Grever MR, Kopecky KJ, Coltman ÇA, et al.: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457-459,1988
4. Keating MJ, Kantarjian H, Talpaz M, et al.: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25,1989
5. Keating MJ, Kantarjian H, O'Brien S, et al.: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49,1991
6. Johnson S, Smith AG, Loffler H, et al. for the The French Cooperative Group on CLL: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347:1432-1438,1996 :
7. Rai KR, Peterson B, Elias L, et al.: A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood 88:141A, 1996 (abstr552, suppl 1)
8. Cheson BD: Infectious and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13:2431-2448,1995
9. Byrd JC, Hargis JB, Kester KE, et al.: Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for Pneumocystis carinpneumonia prophylaxis. Am J Hematol 49:135-142,1995
10. Wijermans PW, Gerrits WBJ, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50:292-296, 1993
11. Byrd JC, Dow NS, Howard RS, et al.: Marked depletion of natural killer cells in chronic lymphocytic leukemia patients receiving fludarabine: A consideration for future immune-based therapy? Proc Am Soc Clin Oncol 16:28a, 1997 (abstr 96)
12. Byrd JC, Weiss RB, Kweeder SL, et al.: Fludarabine therapy for lymphoid malignancies is associated with hemolytic anemia. Proc Am Soc Clin Oncol 13:304,1994 (abstr 991)
13. Bastion Y, Coiffier B, Dumonet C, et al.: Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Ann Oncol 3:171-172,1992
14. Tosti S, Caruso R, D'Adamo F, et al.: Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Ann Hematol 65:238-239, 1992
15. Byrd JC, Hertler AA, Weiss RB, et al.: Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Ann Oncol 6:300-301,1995
16. Kane GC, McMicahel AJ, Patrick H, et al.: Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate.RespirMed 86:261-263,1992
17. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N EnglJMed 333:1052-1057,1995
18. Gilliland BC: Coombs-negative immune hemolytic anemia. Semin Hematol 13:267-275,1976
19. Myint H, Copplestone JA, Orchard J, et al.: Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 91:341-344,1995
20. Fleischman RA, Croy D: Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chIorodeoxyadensine for chronic lymphocytic leukemia. Am J Hematol 48:293,1995 (letter)
21. Di Raimondo F, Giustolisi R, Cacciola E, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11:63-68,1993
22. Sthoeger ZM, Sthoeger D, Shtalrid M, et al.: Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia. Am J Hematol 43:259-264,1993
23. Lewis FB, Schwanz RS, Dameshek W: X-radiation and alkylating agents as possible "trigger" mechanisms in the autoimmune complications of malignant lymphoproliferative disease. Clin Exp Immunol 1:3-11, 1966
24. Kay NE, Howe RB, Douglas SD: Effect of therapy on T cell subpopulations in patients with chronic lymphocytic leukemia. Leuk Res 6:345-348,1982
25. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39:713-716,1986
26. Beutler E, Piro LD, Saven A, et al.: 2-chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 5:1-8,1991